RxDoctor Payments Data

Felipe Suplicy

Psychiatry · Rome, GANPI 1134338908

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $658 of the $848 with a category attached, or 77.7%. Alnylam Pharmaceuticals Inc. accounts for 91.5% of it on its own, with 2 other manufacturers making up the rest.

$848in general payments, 2019–2025

Across 6 payments — averaging $141.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$775
  • AbbVie$49
  • Otsuka America Pharmaceutical, Inc.$23
$2,297,483in research payments, 2019–2025

Across 409 payments — averaging $5617.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axsome Therapeutics, Inc.$585K
  • AbbVie$525K
  • Modernatx, Inc.$418K
  • H. Lundbeck A S$277K
  • Janssen Research & Development, LLC$230K
  • Ipsen Innovation$121K
  • plus $142K from 6 others

What the payments were for

  • Travel & lodging$65878%
  • Food & beverage$18922%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$848 in reported general payments places this provider in the 65th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Other psychiatry in Rome

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →